| Not Yet Recruiting | A Phase 2 Study of HW211026 in Participants With Actinic Keratosis NCT07513454 | Hubei Bio-Pharmaceutical Industrial Technological Institute Inc. | Phase 2 |
| Active Not Recruiting | Study of Reformulated Levulan Kerastick Plus PDT for Actinic Keratosis on Upper Extremities NCT07144852 | Sun Pharmaceutical Industries, Inc. | Phase 3 |
| Active Not Recruiting | Study of Reformulated Levulan Kerastick Plus PDT for Actinic Keratosis on Face and Scalp NCT07144345 | Sun Pharmaceutical Industries, Inc. | Phase 3 |
| Recruiting | The Effect of Topical Imipramine on Photodynamic Therapy-Mediated Immunosuppression on Forearms or Face on US NCT06778434 | VA Office of Research and Development | Phase 2 |
| Completed | Trial to Investigate GZ21T in Healthy Volunteers NCT06888362 | Genzada Pharmaceuticals USA, Inc. | Phase 1 |
| Active Not Recruiting | Testing the Efficacy of Topical Calcipotriene Plus 5-Fluorouracil Combination to Activate the Immune System Ag NCT05699603 | University of Arizona | Phase 2 |
| Completed | Study on the Safety and Efficacy of Bimiralisib Gel in Participants Suffering From Actinic Keratosis NCT06319794 | TORQUR | Phase 2 |
| Completed | Short Contact Protocols to Reduce Pain During 10% ALA Gel Red-light Photodynamic Therapy of Actinic Keratoses NCT06027619 | Case Comprehensive Cancer Center | Phase 2 |
| Completed | Tirbanibulin 1% Ointment for the Treatment of Chronically Sun-damaged Skin on the Face NCT05900258 | Medical University of Graz | Phase 4 |
| Completed | A Study of Tirbanibulin on the Wellbeing of Participants With Actinic Keratoses NCT05741294 | Almirall, S.A. | Phase 4 |
| Recruiting | The Effect of Topical Imipramine on Pain and Effectiveness of Topical Photodynamic Therapy NCT05688904 | Wright State University | Phase 1 |
| Unknown | MRB 0.3% Serum Effectiveness on 2 Early Clinical Markers of Photoinduced Cutaneous Aging: Actinic Lentigo and NCT05152407 | NAOS Institute of Life Science | N/A |
| Completed | A Multi-Center Study to Evaluate the Efficacy and Safety of KX01 Ointment 1% on Actinic Keratosis on Face or S NCT05231044 | PharmaEssentia | Phase 3 |
| Completed | Study to Evaluate Safety and Tolerability of BF-200 ALA (Ameluz®) for Photodynamic Therapy in the Treatment of NCT05060237 | Biofrontera Bioscience GmbH | Phase 1 |
| Unknown | Pain Management During a Photodynamic Therapy Session on the Vertex for Actinic Keratosis: Tumescent Anesthesi NCT04779255 | Poitiers University Hospital | N/A |
| Withdrawn | Daylight Photodynamic Therapy for the Treatment of Actinic Keratoses in the Northeast United States NCT02867722 | Brigham and Women's Hospital | N/A |
| Completed | 5% KOH Solution vs. Placebo and Diclofenac Gel for the Treatment of Actinic Keratosis NCT04552327 | Infectopharm Arzneimittel GmbH | Phase 3 |
| Unknown | Conventional Photodynamic Therapy vs. Painless Photodynamic Therapy for Actinic Keratosis NCT04396184 | Shanghai Dermatology Hospital | N/A |
| Completed | Vitamin D Supplementation as a Neoadjuvant for Photodynamic Therapy of Actinic Keratoses NCT04140292 | Case Comprehensive Cancer Center | Phase 2 |
| Completed | Indoor Daylight Photo Dynamic Therapy for Actinic Keratosis NCT03805737 | Dartmouth-Hitchcock Medical Center | N/A |
| Terminated | Photodynamic Therapy-Induced Immune Modulation: Part III NCT03643744 | Wright State University | Phase 1 |
| Completed | Menthol for PDT Pain Relief NCT02984072 | University of Dundee | Phase 4 |
| Unknown | Topical Ionic Contra-Viral Therapy in Actinic Keratosis NCT03684772 | Maruho Co., Ltd. | Phase 2 |
| Completed | Study to Evaluate the Efficacy, Safety, and Tolerability of Topical VDA-1102 Ointment in Subjects With Actinic NCT03538951 | Vidac Pharma | Phase 2 |
| Completed | Biomarker Database Registry for Photodynamic Therapy NCT03319251 | The Cleveland Clinic | — |
| Completed | A Multi-Center Study to Evaluate the Efficacy and Safety of KX2-391 Ointment 1% on Actinic Keratosis on Face o NCT03285490 | Almirall, S.A. | Phase 3 |
| Completed | DUSA: Cyclic PDT for the Prevention of AK & NMSC in Solid Organ Transplant Recipients NCT03110159 | Medical Dermatology Specialists | Phase 1 / Phase 2 |
| Terminated | A Trial to Compare the Incidence of Squamous Cell Carcinoma (SCC) and Other Skin Neoplasia on Skin Areas Treat NCT03115476 | LEO Pharma | Phase 3 |
| Completed | Safety and Efficacy Study of AM001 Cream in the Treatment of Actinic Keratosis NCT03210740 | AmDerma | Phase 2 |
| Completed | Study of SOR007 Ointment for Actinic Keratosis NCT03083470 | DFB Soria, LLC | Phase 2 |
| Completed | Efficacy of Ingenol Mebutate on Actinic Keratoses and Field Cancerization vs Cryotherapy NCT02990221 | University of Campania Luigi Vanvitelli | Phase 4 |
| Withdrawn | Phase 3 Study of Levulan With New Blue Light for AK on the Face or Scalp NCT03024060 | DUSA Pharmaceuticals, Inc. | Phase 3 |
| Completed | Efficacy of Ablative Fractional Laser-assisted Photodynamic Therapy According to the Laser Density for Actinic NCT03731988 | Dong-A University | Phase 4 |
| Completed | Perimenstrual Acne With Clindamycin Phosphate and Benzoyl Peroxide NCT03122457 | Icahn School of Medicine at Mount Sinai | Phase 2 |
| Completed | Study Comparing GDC 695 and Diclofenac Sodium Gel, 3% in Subjects With Actinic Keratoses NCT02952898 | Balmoral Medical company | Phase 3 |
| Completed | Safety and Efficacy of Ingenol Mebutate Gel 0.015% for Treatment of AK on the Face in Solid Organ Transplant R NCT02866695 | University of California, San Francisco | Phase 4 |
| Completed | Pilot Study of the Pragmatic Use of Mobile Phone Based Follow up of Actinic Keratoses Treated With Topical 5-f NCT02938715 | University of California, Davis | N/A |
| Completed | Potential Impact of Patient Vitamin D Status in AK Response to MAL-PDT NCT02878382 | University of Sao Paulo | N/A |
| Completed | Tele-dermatology of Skin Cancer in a Cohort of Local Health Authority Employees in the Province of Bergamo NCT02902822 | Centro Studi Gised | N/A |
| Unknown | Daylight Photodynamic Therapy for Actinic Keratosis and Skin Field Cancerization NCT03013647 | University of Sao Paulo General Hospital | N/A |
| Completed | An Equivalence Study of Generic Ingenol Mebutate Gel 0.015% and Picato Gel 0.015% in Subjects With Actinic Ker NCT03200912 | Actavis Inc. | Phase 3 |
| Completed | Laser and Microdermabrasion Before Photodynamic Therapy for Actinic Keratoses in Field-cancerized Skin NCT03006185 | Bispebjerg Hospital | Phase 2 |
| Completed | Efficacy and Safety of VDA-1102 Ointment in the Treatment of Actinic Keratosis NCT02844777 | Vidac Pharma | Phase 2 |
| Completed | Biological Effects of LEO 43204 in Actinic Keratosis NCT02600598 | LEO Pharma | Phase 1 |
| Completed | Activity & Safety Study of KX2-391 Ointment in Participants With Actinic Keratosis on the Face or Scalp NCT02838628 | Almirall, S.A. | Phase 2 |
| Completed | Microneedle Lesion Preparation Prior to Aminolevulinic Acid Photodynamic Therapy (ALA-PDT) for AK on Face NCT02632110 | DUSA Pharmaceuticals, Inc. | Phase 2 |
| Completed | A Clinical Study to Evaluate the Sensitizing Potential of LEO 43204 Gel NCT02650505 | LEO Pharma | Phase 1 |
| Unknown | Using a Cold Atmospheric Plasma Device to Treat Skin Disorders NCT02759900 | The Skin Center Dermatology Group | N/A |
| Completed | The Use of Picato® (Ingenol Mebutate) to Treat Actinic Keratosis in Standard Clinical Practice NCT02594436 | LEO Pharma | — |
| Unknown | Efficacy and Safety of Treatment of Actinic Keratoses With Photodynamic Therapy Between MAL Cream and ALA Gel NCT02647151 | Fundación Instituto Valenciano de Oncología | Phase 4 |
| Completed | Efficacy and Safety of LEO 43204 in the Field Treatment of Actinic Keratosis on Face or Chest including12-mont NCT02549339 | LEO Pharma | Phase 3 |
| Completed | Clinical and Histologic Evaluation of Picato 0.15% Gel in the Cosmetic Improvement of Photoaged Skin NCT03508856 | Skin Laser & Surgery Specialists | N/A |
| Completed | Efficacy and Safety of LEO 43204 in Field Treatment of Actinic Keratosis on Balding Scalp Including 12-month F NCT02547363 | LEO Pharma | Phase 3 |
| Completed | Efficacy and Safety of LEO 43204 in Field Treatment of Actinic Keratosis on Face or Chest Including 12-month F NCT02547233 | LEO Pharma | Phase 3 |
| Completed | Eight Week Study of Treatment With DFD-07 for Actinic Keratosis of the Face and Scalp NCT02654717 | Promius Pharma, LLC | Phase 2 |
| Completed | Multiple-dose Pharmacokinetic Study of Solamargine in Patients With Actinic Keratosis NCT02559934 | G&E Herbal Biotechnology Co., LTD | Phase 1 |
| Completed | Efficacy and Safety of LEO 43204 in Field Treatment of Actinic Keratosis on Balding Scalp Including 12-month F NCT02549352 | LEO Pharma | Phase 3 |
| Completed | A Randomized, Double-Blind, Parallel-Group, Vehicle-Controlled, Multicenter Study Comparing Diclofenac Sodium NCT02611804 | Teva Pharmaceuticals USA | Phase 3 |
| Completed | Metvix Daylight PDT in Actinic Keratosis NCT02674048 | Galderma R&D | — |
| Terminated | Ingenol Mebutate Gel 0.05% in Kidney Transplant Recipients With Actinic Keratoses NCT02473848 | Günther Hofbauer | Phase 3 |
| Completed | Daylight PDT for Actinic Keratoses: a Multicentre Study Comparing Two Photosensitizers (BF-200 ALA Versus MAL) NCT02464709 | Joint Authority for Päijät-Häme Social and Health Care | Phase 4 |
| Completed | Pharmacokinetics of LEO 43204 Gel in Actinic Keratosis Administered Under Maximal Use Conditions NCT02424305 | LEO Pharma | Phase 1 |
| Completed | To Compare Safety and Efficacy of Perrigo's Drug Compared to an FDA Approved Drug in the Treatment of Actinic NCT02459795 | Padagis LLC | Phase 3 |
| Completed | Study of Daylight Photodynamic Therapy With Aminolevulinic Acid for Actinic Keratoses NCT03327831 | University of California, Irvine | Phase 4 |
| Completed | Clinical Trial of Ingenol Mebutate Gel 0.015% & 0.05% in Actinic Keratosis NCT02716714 | Korea University | Phase 4 |
| Completed | Efficacy and Safety of Ingenol Mebutate Gel for Actinic Keratosis Applied on Large Area on Face, Scalp or Ches NCT02361216 | LEO Pharma | Phase 3 |
| Completed | Safety, Tolerability, and Efficacy Study of LFX453 in Actinic Keratosis Patients NCT02404389 | Novartis Pharmaceuticals | Phase 2 |
| Completed | Safety of LEO 43204 for Actinic Keratosis Applied on Face/Chest, Scalp and Trunk/Extremities, Respectively NCT02305888 | LEO Pharma | Phase 2 |
| Completed | Multicenter, Double-blind, Placebo Controlled Comparing Test Fluorouracil Cream to Carac Cream in Actinic Kera NCT02616601 | Actavis Inc. | Phase 3 |
| Completed | A Study of Equivalence of Generic Ingenol Mebutate Gel 0.05% and Picato Gel 0.05% in Subjects With Actinic Ker NCT02654769 | Actavis Inc. | Phase 3 |
| Completed | To Compare Safety and Efficacy of Perrigo's Drug Product Compared to an FDA Approved Drug Product in the Treat NCT02385318 | Padagis LLC | Phase 3 |
| Unknown | Ingenol Mebutate (Picato®) With Methyl Aminolevulinate Photodynamic Therapy for the Treatment of Actinic Kerat NCT02354391 | Pacific Dermaesthetics | Phase 2 |
| Completed | Evaluate the Efficacy and Safety of Large-Scale Field-Directed Topical Therapy of Actinic Keratosis of the Che NCT02446223 | Goldman, Butterwick, Fitzpatrick and Groff | Phase 4 |
| Completed | Ph 1, Single-Center, Safety, Tolerability & Pharmacokinetic Study of KX2 391 Ointment in Subj. w Actinic Kerat NCT02337205 | Athenex, Inc. | Phase 1 |
| Completed | Open Uncontrolled Validation Study for the German Version of the Actinic Keratosis Quality of Life Questionnai NCT02325661 | University of Zurich | N/A |
| Completed | Study To Evaluate The Efficacy And Safety Of Actikerall® Solution In Patients With Grade I-II Actinic Keratose NCT02289768 | Almirall, S.A. | Phase 3 |
| Completed | Controlled Study of the Occurrence of Actinic Keratosis on the Face After Cryotherapy + Aminolevulinic Acid (A NCT02239679 | DUSA Pharmaceuticals, Inc. | Phase 2 |
| Completed | PMS to Evaluate the Safety and Efficacy of Picato® Gel NCT02421471 | LEO Pharma | — |
| Terminated | Treatment of Field Cancerization for Reduction in Tumor Burden - A Prospective Study NCT02150863 | Massachusetts General Hospital | N/A |
| Completed | Twelve Month Follow-Up of CP0108 NCT02209012 | DUSA Pharmaceuticals, Inc. | — |
| Completed | The Real Life Topical Field Treatment of Actinic Keratosis Study NCT02362152 | LEO Pharma | — |
| Completed | Efficacy of Iontophoresis-assisted AFL-PDT in Actinic Keratosis NCT02670655 | Dong-A University | Phase 1 |
| Completed | Safety and Efficacy Study of Photodynamic Therapy With Levulan Kerastick + Blue Light for Actinic Keratoses on NCT02137785 | DUSA Pharmaceuticals, Inc. | Phase 3 |
| Completed | Safety and Efficacy of Escalating Doses of LEO 43204 Applied Once Daily for Two Consecutive Days on Approximat NCT02120456 | LEO Pharma | Phase 1 / Phase 2 |
| Completed | Safety and Tolerability Study of Ingenol Mebutate Compared to 5-FU to Treat Facial Actinic Keratosis NCT02242747 | University of Sao Paulo | N/A |
| Completed | Safety and Efficacy of Doses of LEO 43204 Once Daily for Two Consecutive Days on Full Balding Scalp in Subject NCT02100813 | LEO Pharma | Phase 1 / Phase 2 |
| Completed | ACT01 in Combination With Comp01-04 in Patients With Actinic Keratosis NCT02126670 | Promius Pharma, LLC | Phase 2 |
| Completed | TreatMent of ActInic KerAtosis Lesions : pharmacoepiDemiological Study of the Impact in Real Life of ingenOl M NCT04202445 | LEO Pharma | — |
| Completed | Pharmacokinetics of Ingenol Mebutate Gel in Actinic Keratosis Under Maximum Use Conditions NCT02124239 | LEO Pharma | Phase 1 |
| Completed | Protocols for Painless Photodynamic Therapy (PDT) of Actinic Keratoses NCT02124733 | The Cleveland Clinic | Phase 3 |
| Completed | Efficacy and Safety of Ingenol Mebutate Gel 0.06% When Applied Once Daily for 2, 3 or 4 Consecutive Days to a NCT01998984 | LEO Pharma | Phase 2 |
| Completed | Pharmacokinetic Study of Solamargine in Patients With Actinic Keratosis NCT02029066 | G&E Herbal Biotechnology Co., LTD | Phase 1 |
| Completed | A Study to Evaluate the Safety and Efficacy Imiquimod Cream, 2.5% in Participants With Actinic Keratoses NCT02120898 | Actavis Inc. | Phase 3 |
| Completed | A Study of Increasing Strengths, Safety and Efficacy of Two Formulas of LEO 43204 on the Face or the Chest in NCT01922050 | LEO Pharma | Phase 1 / Phase 2 |
| Completed | Safety and Efficacy Study for the Field-directed Treatment of Actinic Keratosis (AK) With Photodynamic Therapy NCT01966120 | Biofrontera Bioscience GmbH | Phase 3 |
| Completed | Actinic Keratosis Study NCT02019355 | Washington University School of Medicine | EARLY_Phase 1 |
| Completed | Fractional Laser-assisted Daylight Photodynamic Therapy Versus Daylight Photodynamic for Treatment of Actinic NCT01898936 | Oslo University Hospital | N/A |
| Completed | Nanocytology Test to Evaluate Skin Cancer in High Risk Patients NCT01905891 | Northwestern University | N/A |
| Completed | Assessment of Treatment Success and Quality of Life in Patients With Actinic Keratoses Under Therapy With Inge NCT02090465 | LEO Pharma | — |
| Completed | Histological Confirmation of Clinical Clearance of Actinic Keratoses Following Treatment With Ingenol Mebutate NCT01892137 | LEO Pharma | Phase 1 |
| Completed | Safety and Efficacy of Ingenol Mebutate Once Daily for 2 or 3 Consecutive Days in Subjects With Actinic Kerato NCT01820260 | LEO Pharma | Phase 1 / Phase 2 |
| Completed | Ingenol Mebutate 0.015% Gel in the Treatment of Actinic Keratoses (AK) on the Face and Scalp NCT01836367 | Icahn School of Medicine at Mount Sinai | Phase 1 |
| Completed | A Study Comparing Diclofenac Sodium Gel 3% to Solaraze® (Diclofenac Sodium) Gel 3% in the Treatment of Actinic NCT01962987 | Actavis Inc. | Phase 3 |
| Completed | A Simultaneous Treatment Regimen Compared to a Sequential Treatment Regimen With Ingenol Mebutate Gel 0.015% a NCT01787383 | LEO Pharma | Phase 3 |
| Completed | Safety and Dose Finding Study of New Vehicle Formulations Containing Ingenol Mebutate to Treat Actinic Keratos NCT01803477 | LEO Pharma | Phase 1 / Phase 2 |
| Completed | Efficacy and Safety Phase II Study of SR-T100 to Treat Actinic Keratosis NCT01516515 | G&E Herbal Biotechnology Co., LTD | Phase 2 |
| Completed | Clinical Study to Evaluate the Bioequivalence of Two Imiquimod Cream 3.75% Formulations in Patients With Actin NCT01788007 | Sun Pharmaceutical Industries, Inc. | Phase 1 |
| Terminated | Observational Trial Tolerability and Efficacy of Resiquimod Gel in Patients Treated for Actinic Keratosis. NCT01806961 | Spirig Pharma Ltd. | — |
| Completed | Genomic Markers Before and After Treatment of Actinic Keratosis With Imiquimod 3.75% Cream NCT03914417 | Icahn School of Medicine at Mount Sinai | Phase 2 |
| Completed | Safety and Tolerability of Different Concentrations of an Ingenol Derivative Field Therapy in the Treatment of NCT01703078 | LEO Pharma | Phase 1 |
| Completed | A Study Comparing Diclofenac Sodium Gel 3% to Solaraze® Gel 3% in the Treatment of Actinic Keratosis NCT01742663 | Sun Pharmaceutical Industries, Inc. | Phase 1 |
| Withdrawn | Ingenol Mebutate Compared to Cryotherapy for the Treatment of Skin Lesions NCT01735942 | Northwestern University | EARLY_Phase 1 |
| Completed | Study Comparing Imiquimod Cream, 3.75% to Zyclara® (Imiquimod) Cream, 3.75% in the Treatment of Actinic Kerato NCT01686152 | Teva Pharmaceuticals USA | Phase 3 |
| Unknown | Long Term Efficacy and Safety of Eryfotona AK-NMSC® in Patients With Actinic Keratosis NCT01656226 | ISDIN | Phase 4 |
| Completed | The Use of Microneedles in Photodynamic Therapy NCT01812837 | University of California, Davis | N/A |
| Completed | Ingenol Mebutate Gel, 0.015% Repeat Use for Multiple Actinic Keratoses on Face and Scalp NCT01600014 | LEO Pharma | Phase 3 |
| Completed | Dose-finding, Safety, Efficacy Trial of Topical Resiquimod in Patients With Multiple Actinic Keratosis Lesions NCT01583816 | Spirig Pharma Ltd. | Phase 2 |
| Completed | Photodynamic Therapy of Actinic Keratoses With Alacare® NCT01571336 | photonamic GmbH & Co. KG | — |
| Completed | A Sequential Treatment Regimen of Cryotherapy and Picato® for the Treatment of Actinic Keratosis on the Face a NCT01541553 | LEO Pharma | Phase 3 |
| Completed | Efficacy of AFL-assisted PDT With Short Incubation Time in Actinic Keratosis NCT02248298 | Dong-A University | Phase 1 |
| Completed | Short-incubation Levulan Photodynamic Therapy Versus Vehicle for Face/Scalp Actinic Keratosis (AK) NCT01475955 | DUSA Pharmaceuticals, Inc. | Phase 2 |
| Completed | Oral Isotretinoin Versus Topical Tretinoin for Actinic Keratosis NCT02278861 | Universidade Federal de Goias | Phase 2 |
| Completed | Efficacy Study & Safety Evaluation of SR-T100 Gel in Actinic Keratosis Treatment NCT01493921 | G&E Herbal Biotechnology Co., LTD | Phase 3 |
| Completed | Long-term Effects of Imiquimod and Diclofenac in Actinic Keratoses (LEIDA 2) NCT01453179 | MEDA Pharma GmbH & Co. KG | Phase 4 |
| Completed | Development and Validation of a Quality of Life Instrument for Actinic Keratosis NCT01444989 | Wake Forest University | N/A |
| Completed | PEP005 Gel - Biological Effects in Actinic Keratosis Assessed by Reflectance Confocal Microscopy NCT01449513 | LEO Pharma | Phase 1 |
| Terminated | Combination Therapy With 5-Fluorouracil and Photodynamic Therapy in Post-transplant Premalignant Skin Disease NCT01525329 | The Cleveland Clinic | Phase 3 |
| Completed | PEP005 Gel - Biological Effects in Actinic Keratosis Assessed by Histology NCT01387711 | LEO Pharma | Phase 1 |
| Unknown | Potential Effect of Topical Imiquimod on Atrial Ectopy in Patients With Actinic Keratosis NCT01413763 | Medicis Global Service Corporation | Phase 4 |
| Completed | LAS41005 in Hyperkeratotic Actinic Keratosis NCT01358851 | Almirall, S.A. | Phase 2 |
| Unknown | Comparative Study of Photodynamic Therapy vs. CO2 Laser Therapy in Treatment of Actinic Keratoses NCT01481155 | Ruhr University of Bochum | N/A |
| Completed | PEP005 Gel - Evaluation of Local Tolerability After Exposure to Ingenol Mebutate Gel Followed by Hand Washing NCT01302925 | Peplin | Phase 1 |
| Completed | Cryosurgery and Cream Combination for Actinic Keratosis NCT03037541 | Wake Forest University Health Sciences | Phase 3 |
| Completed | Comparison Between 5-aminolevulinic Acid Photodynamic Therapy Versus Cryotherapy for Actinic Keratosis Treatme NCT01459393 | Barretos Cancer Hospital | Phase 3 |
| Completed | Double-blind, Randomized, Vehicle- and Comparator-controlled, Multi-center Trial to Evaluate the Efficacy and NCT01265602 | Almirall, S.A. | Phase 3 |
| Completed | Fractional CO2 Laser Assisted Photodynamic Therapy NCT01260987 | Bispebjerg Hospital | Phase 2 / Phase 3 |
| Unknown | Imiquimod 3.75% Cream in Combination With Cryotherapy in the Treatment of Hypertrophic Actinic Keratoses NCT01229319 | Frankel, Amylynne, M.D. | Phase 4 |
| Terminated | Treatment of Actinic Keratoses of the Face With Imiquimod 3.75% Cream Followed by Photodynamic Therapy NCT01203878 | Tennessee Clinical Research Center | Phase 4 |
| Unknown | 5fluorouracil for Advanced Photoaging NCT01405144 | Federal University of São Paulo | Phase 3 |
| Completed | Photodynamic Treatment of Actinic Keratoses With Different Light Doses NCT01541228 | Lithuanian University of Health Sciences | N/A |
| Completed | Gene Expression in Renal Transplant Patients With Field Actinic Keratosis Undergoing Metvix® Photodynamic Ther NCT01000636 | Galderma R&D | Phase 4 |
| Completed | A Long Term Follow up Study of Patients Who Have Complete Clearance of Their Actinic Keratosis (AK) Lesions at NCT00989313 | Peplin | — |
| Completed | Efficacy and Safety Study of LAS41007 in the Treatment of Actinic Keratosis NCT00991861 | Almirall, S.A. | Phase 2 |
| Completed | A Long Term Follow up Study of Patients Who Have Completed the PEP005-016 or PEP005-025 Studies NCT00953732 | Peplin | — |
| Completed | Short Incubation Methylaminolevulinate Photodynamic Therapy Without Occlusion NCT00926952 | Innovaderm Research Inc. | Phase 3 |
| Completed | A Long Term Follow up Study of Patients Who Have Completed the PEP005-020 Study NCT00952783 | Peplin | — |
| Completed | A Multi-Center Study to Evaluate the Efficacy and Safety of PEP005 (Ingenol Mebutate) Gel, When Used to Treat NCT00915551 | Peplin | Phase 3 |
| Completed | A Multi-center Study to Evaluate the Safety and Efficacy of PEP005 (Ingenol Mebutate) Gel, When Used to Treat NCT00917306 | Peplin | Phase 3 |
| Completed | A Multi-center Study to Evaluate the Efficacy and Safety of PEP005 (Ingenol Mebutate) Gel, When Used to Treat NCT00916006 | Peplin | Phase 3 |
| Completed | Safety and Effectiveness Study of Actinic Keratosis Treatment Following Cryosurgery NCT00894647 | Graceway Pharmaceuticals, LLC | Phase 3 |
| Completed | A Study to Evaluate the Pharmacokinetics of PEP005 (Ingenol Mebutate) Gel, 0.05%, When Applied in a Maximal Us NCT00852137 | Peplin | Phase 2 |
| Completed | A Study to Evaluate the Photoallergic Potential of PEP005 (Ingenol Mebutate) Gel, 0.01% in Healthy Volunteers NCT00850681 | Peplin | Phase 1 |
| Completed | A Study to Evaluate the Photoirritation Potential of PEP005 (Ingenol Mebutate) Gel, 0.01% in Healthy Volunteer NCT00850811 | Peplin | Phase 1 |
| Completed | Photodynamic Therapy (PDT) Effect on Large Surface Photodamaged Skin NCT00843323 | University of Sao Paulo | N/A |
| Completed | Long-term Effects of Imiquimod and Diclofenac in Actinic Keratoses NCT00777127 | MEDA Pharma GmbH & Co. KG | Phase 4 |
| Completed | Study on the Efficacy of LAS41005 in the Treatment of Actinic Keratosis NCT00987246 | Almirall, S.A. | Phase 3 |
| Completed | Bioequivalence Study of Two Imiquimod Cream 5% NCT00828568 | Sun Pharmaceutical Industries, Inc. | Phase 1 |
| Completed | A Multicenter Study to Evaluate the Safety and Efficacy of PEP005 Topical Gel When Used to Treat Actinic Kerat NCT00700063 | Peplin | Phase 2 |
| Completed | Potential Research Study Participant Registry NCT00710489 | University of California, Davis | — |
| Completed | Imiquimod and Actinic Keratoses: an Observational Study NCT01151956 | Federal University Teaching Hospital, Feldkirch, Austria | — |
| Completed | Safety and Toleration of PEP005 Topical Gel When Applied to a Treatment Area of up to 100cm2 NCT00659893 | Peplin | Phase 1 |
| Completed | Evaluation of Safety and Efficacy of BF-200 ALA for the Treatment of Actinic Keratosis With Photodynamic Thera NCT02799069 | Biofrontera Bioscience GmbH | Phase 3 |
| Completed | A Randomized, Double-Blind, Parallel-Group, Vehicle-Controlled Therapeutic Equivalence Study of Three Imiquimo NCT00859105 | Apotex Inc. | Phase 3 |
| Completed | Safety and Effectiveness Study of Imiquimod Creams for the Treatment of Actinic Keratoses (AKs) NCT00603798 | Graceway Pharmaceuticals, LLC | Phase 3 |
| Completed | Evaluation of Efficacy and Safety of BF-200 ALA Used With Photodynamic Therapy in Patients With Actinic Kerato NCT02799082 | Biofrontera Bioscience GmbH | Phase 3 |
| Withdrawn | Photodynamic Therapy Mediated by Topical Application of 5- ALA for the Treatment of Actinic Keratoses NCT00814528 | University of Chicago | N/A |
| Completed | Clinical Study Assessment of SR-T100 Topical Gel Against Actinic Keratosis NCT02085395 | G&E Herbal Biotechnology Co., LTD | Phase 2 |
| Completed | A Study to Examine the Safety and Toleration of PEP005 Topical Gel in Patients With Actinic Keratoses on the T NCT00544297 | Peplin | Phase 2 |
| Completed | Metvix PDT Versus Vehicle PDT With Aktilite CL128 Lamp in Patients With Actinic Keratosis on the Face and Scal NCT00306800 | Galderma R&D | Phase 3 |
| Completed | Measuring Adherence To Topical 5-Fluorouracil in a Clinic Population NCT00696488 | Wake Forest University | Phase 4 |
| Completed | A Clinical Trial of Topical Photodynamic Therapy With 5-aminolevulinic Acid for the Treatment of Actinic Kerat NCT02799030 | Biofrontera Bioscience GmbH | Phase 2 |
| Completed | Clinical Trial to Evaluate Biafine Cream Versus Standard Care in Subjects With Actinic Keratosis Post Cryother NCT00695578 | Wake Forest University | Phase 4 |
| Completed | Study to Determine the Safety of PEP005 0.025% and 0.05% Topical Gel in Patients With Actinic Keratoses NCT00375739 | Peplin | Phase 2 |
| Completed | Metvix PDT Versus Vehicle PDT With Aktilite CL128 Lamp in Patients With Actinic Keratosis on the Face and Scal NCT00304239 | Galderma R&D | Phase 3 |
| Completed | Photodynamic Therapy With PD P 506 A Compared With Placebo-PDT for the Treatment of AK NCT00308854 | photonamic GmbH & Co. KG | Phase 3 |
| Completed | PD P 506 A-PDT Versus Placebo-PDT and Cryosurgery for the Treatment of AK NCT00308867 | photonamic GmbH & Co. KG | Phase 3 |
| Completed | Evaluation of Two Different Non-invasive Techniques to Monitor the Clearance of Actinic Keratosis Lesions NCT00294320 | MEDA Pharma GmbH & Co. KG | Phase 3 |
| Completed | Effect of IDEA-070 on Pain and Inflammation Induced by PDT NCT00269074 | IDEA AG | Phase 2 |
| Completed | Study of Imiquimod 5% Cream in Addition to Cryotherapy in the Management of Actinic Keratoses NCT00110682 | Derm Research @ 888 Inc. | Phase 4 |
| Completed | Study to Determine the Safety of Two Applications of PEP005 Topical Gel to Actinic Keratoses NCT00107965 | Peplin | Phase 2 |
| Completed | T4N5 Liposomal Lotion in Preventing The Recurrence of Nonmelanoma Skin Cancer in Patients Who Have Undergone a NCT00089180 | National Cancer Institute (NCI) | Phase 2 |
| Completed | Photodynamic Therapy (PDT) With Metvix® 160 Milligrams/Gram Cream in Organ Transplant Participants With Non-me NCT00472459 | Galderma R&D | Phase 3 |
| Completed | Cellular and Molecular Events During Treatment of Actinic Keratosis With Imiquimod 5% Cream NCT00335179 | Graceway Pharmaceuticals, LLC | Phase 2 |
| Completed | A Study to Evaluate the Effectiveness and Safety of Multiple Applications of Imiquimod 5% Cream for the Treatm NCT00189267 | MEDA Pharma GmbH & Co. KG | Phase 2 |
| Completed | Efficacy and Safety of a New Topical Formulation With Imiquimod (Limtop) Applied 1, 3 or 7 Times Weekly During NCT01611480 | Moberg Pharma AB | Phase 2 |